Michael Vasconcelles
CIK 1734755 · Head of Research and Dev. · last filed 2026-11-03
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
DAWN price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
200 CAMBRIDGEPARK DR., STE. 3100
CAMBRIDGE, MA 02140
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| MGNX | Director | — | $1.99 | — | $0 | 1 | 2026-11-03 |
| KURA | Director | — | $7.39 | — | $0 | 3 | 2026-06-04 |
| Day One Biopharmaceuticals, Inc. (DAWN) Delisted | Head of Research and Dev. | 0 | $21.53 | $0 | -$31.6K | 4 | 2026-04-23 |
| ImmunoGen, Inc. (IMGN) Delisted | EVP R&D & MEDICAL AFFAIRS | 0 | $31.23 | $0 | $0 | 4 | 2024-02-12 |
| Dianthus Therapeutics, Inc. /DE/ (MGTA) Delisted | Director | — | $11.19 | — | $0 | 1 | 2022-08-17 |
| Cogent Biosciences, Inc. (UMRX) Delisted | Chief Medical Officer | — | — | — | $0 | 1 | 2019-04-11 |
Recent Filings · Page 2 of 2
14 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2024-01-03 | ImmunoGen, Inc. (IMGN) Delisted | Grant (A) | +1,327 | $21.2K | EDGAR |
| 2023-01-03 | ImmunoGen, Inc. (IMGN) Delisted | Grant (A) | — | $0 | EDGAR |
| 2022-08-17 | Dianthus Therapeutics, Inc. /DE/ (MGTA) Delisted | Grant (A) | — | $0 | EDGAR |
| 2019-04-11 | Cogent Biosciences, Inc. (UMRX) Delisted | Grant (A) | — | $0 | EDGAR |
10b5-1: the filer ticked the box for trades made under a Rule 10b5-1 trading plan, which sets the sales (or buys) in advance, so they say less about the insider's view at the time than a discretionary trade. The plan's adoption date is shown when the filing's footnotes give it.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment, and an amended or cancelled notice is not listed. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes. Someone who is no longer an officer or director (or never was) files no Form 4, so for them a sale shows up only on a later notice, which lists the seller's sales from the 3 months before it. "No sale on file" means neither record shows one; a dash in Net $ means the value filed on the notice doesn't fit the stock's price (likely a typo).